Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:ANL NASDAQ:FENC NASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.35-1.7%$1.79$0.87▼$6.37$241.90M0.861.62 million shs465,077 shsANLAdlai Nortye$1.69+0.9%$1.57$1.10▼$3.89$61.83M-0.958,868 shs1,748 shsFENCAdherex Technologies$8.87$8.52$3.96▼$9.42$246.71M0.468,267 shs31,949 shsTKNOAlpha Teknova$4.32+0.2%$4.72$4.00▼$10.37$230.65M0.32231,980 shs84,967 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-1.67%-6.75%+46.88%+74.72%-54.89%ANLAdlai Nortye+0.86%+1.44%+18.18%-9.14%-43.43%FENCAdherex Technologies0.00%+2.42%+5.47%+10.46%+63.05%TKNOAlpha Teknova+0.23%-9.05%-10.74%-25.00%-7.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.997 of 5 stars3.12.00.04.53.22.50.0ANLAdlai Nortye1.6659 of 5 stars3.03.00.00.03.30.00.0FENCAdherex Technologies2.1064 of 5 stars3.51.00.00.02.82.50.0TKNOAlpha Teknova2.4187 of 5 stars3.81.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.29Hold$4.1777.30% UpsideANLAdlai Nortye 2.00Hold$9.00432.54% UpsideFENCAdherex Technologies 3.00Buy$13.3350.32% UpsideTKNOAlpha Teknova 3.50Strong Buy$10.00131.48% UpsideCurrent Analyst Ratings BreakdownLatest ANL, TKNO, FENC, and ALEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.008/15/2025FENCAdherex TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.007/28/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.50 ➝ $3.507/22/2025TKNOAlpha TeknovaStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.006/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M2.37N/AN/A$0.70 per share3.36ANLAdlai Nortye$5M12.47N/AN/A$0.69 per share2.45FENCAdherex Technologies$47.54M5.19$0.03 per share274.65($0.27) per share-32.85TKNOAlpha Teknova$38.92M5.94N/AN/A$1.42 per share3.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)ANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/AN/AFENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)TKNOAlpha Teknova-$26.75M-$0.42N/AN/AN/A-55.24%-26.51%-18.40%11/6/2025 (Estimated)Latest ANL, TKNO, FENC, and ALEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/7/2025Q2 2025TKNOAlpha Teknova-$0.1004-$0.07+$0.0304-$0.07$9.90 million$10.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78ANLAdlai Nortye0.021.411.41FENCAdherex TechnologiesN/A4.854.59TKNOAlpha Teknova0.175.874.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ANLAdlai Nortye35.21%FENCAdherex Technologies55.51%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%ANLAdlai NortyeN/AFENCAdherex Technologies11.76%TKNOAlpha Teknova12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableFENCAdherex Technologies1027.81 million24.54 millionOptionableTKNOAlpha Teknova24053.52 million46.83 millionNot OptionableANL, TKNO, FENC, and ALEC HeadlinesRecent News About These CompaniesAlpha Teknova (NASDAQ:TKNO) Announces Earnings ResultsAugust 11, 2025 | marketbeat.comAlpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comAlpha Teknova (TKNO) Q2 Revenue Jumps 7%August 8, 2025 | aol.comACenterBook Partners LP Takes Position in Alpha Teknova, Inc. (NASDAQ:TKNO)August 8, 2025 | marketbeat.comTeknova Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comTeknova to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.comPleasing Signs As A Number Of Insiders Buy Alpha Teknova StockJuly 9, 2025 | finance.yahoo.comMartha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) StockJuly 2, 2025 | insidertrades.comAlpha Teknova, Inc. (TKNO) Income Statement - Yahoo FinanceJune 28, 2025 | ca.finance.yahoo.comAlpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comAlpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comTeknova Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAlpha Teknova (TKNO) Traded Lower on Increased UncertaintyApril 30, 2025 | msn.comAlpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comQTeknova to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comAlpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation systemMarch 20, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | globenewswire.comTeknova, Pluristyx announce collaboration over next-generation cell therapiesMarch 11, 2025 | markets.businessinsider.comTeknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell TherapiesMarch 11, 2025 | globenewswire.comEarnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67March 8, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?By Leo Miller | August 13, 2025ANL, TKNO, FENC, and ALEC Company DescriptionsAlector NASDAQ:ALEC$2.35 -0.04 (-1.67%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.35 0.00 (-0.21%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Adlai Nortye NASDAQ:ANL$1.69 +0.01 (+0.86%) Closing price 08/29/2025 03:46 PM EasternExtended Trading$1.67 -0.02 (-1.18%) As of 08/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Adherex Technologies NASDAQ:FENC$8.87 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.88 +0.01 (+0.06%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Alpha Teknova NASDAQ:TKNO$4.32 +0.01 (+0.23%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.32 0.00 (0.00%) As of 08/29/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
